Biomea Fusion/$BMEA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Biomea Fusion
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Ticker
$BMEA
Sector
Primary listing
Employees
41
Headquarters
Website
Biomea Fusion Metrics
BasicAdvanced
$137M
-
-$1.18
-0.27
-
Price and volume
Market cap
$137M
Beta
-0.27
52-week high
$3.08
52-week low
$0.87
Average daily volume
1.4M
Financial strength
Current ratio
5.229
Quick ratio
5.028
Long term debt to equity
0.433
Total debt to equity
5.377
Profitability
EBITDA (TTM)
-79.898
Management effectiveness
Return on assets (TTM)
-73.38%
Return on equity (TTM)
-152.35%
Valuation
Price to book
4.65
Price to tangible book (TTM)
4.65
Price to free cash flow (TTM)
-1.41
Free cash flow yield (TTM)
-70.91%
Free cash flow per share (TTM)
-1.347
Growth
Earnings per share change (TTM)
-69.14%
3-year earnings per share growth (CAGR)
-24.92%
What the Analysts think about Biomea Fusion
Analyst ratings (Buy, Hold, Sell) for Biomea Fusion stock.
Biomea Fusion Financial Performance
Revenues and expenses
Biomea Fusion Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Biomea Fusion stock?
Biomea Fusion (BMEA) has a market cap of $137M as of April 08, 2026.
What is the P/E ratio for Biomea Fusion stock?
The price to earnings (P/E) ratio for Biomea Fusion (BMEA) stock is 0 as of April 08, 2026.
Does Biomea Fusion stock pay dividends?
No, Biomea Fusion (BMEA) stock does not pay dividends to its shareholders as of April 08, 2026.
When is the next Biomea Fusion dividend payment date?
Biomea Fusion (BMEA) stock does not pay dividends to its shareholders.
What is the beta indicator for Biomea Fusion?
Biomea Fusion (BMEA) has a beta rating of -0.27. This means that it has an inverse relation to market volatility.